Exchange: NASDAQ·Updated 04:20 PM EST

SEPN News

News
all
press releases
Septerna (NASDAQ:SEPN) Director Alan Ezekowitz Sells 81,820 Shares of Stock
Septerna, Inc. (NASDAQ:SEPN - Get Free Report) Director Alan Ezekowitz sold 81,820 shares of the business's stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $48.09, for a total value of $3,934,723.80. Following the completion of the transaction, the...
MarketBeat
Septerna (NASDAQ:SEPN) Director Alan Ezekowitz Sells 81,820 Shares of Stock
Septerna, Inc. (NASDAQ:SEPN - Get Free Report) Director Alan Ezekowitz sold 81,820 shares of the business's stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $48.09, for a total value of $3,934,723.80. Following the completion of the transaction, the...
MarketBeat
More News
Septerna, Inc. (SEPN) delivered earnings and revenue surprises of -3.64% and -19.52%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Moderna (MRNA) delivered earnings and revenue surprises of +134.55% and +47.73%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Puma Biotech (PBYI) delivered earnings and revenue surprises of +36.36% and -3.54%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of +20.90% and +196.50%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Septerna, Inc. (SEPN) delivered earnings and revenue surprises of +39.58% and +30.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 0.00% and -35.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of +12.93% and +2.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Key PointsSamira Shaikhly sold 11,798 shares of Common Stock on May 26, 2026, for a transaction value of ~$355,000...
Nasdaq News: Markets
Key Points15,000 shares were exercised and sold for a total of ~$533,000 on June 22, 2026, at a weighted average price of around $35.51 per share...
Nasdaq News: Markets

Advertisement|Remove ads.